Showing results (1-10 of 226) with videos related to
Sort By:
Pageof 23
Clinical Pharmacology and Therapeutics|November 4, 2025
Toward a More accurate, Evidence-Based Classification of CYP Inhibitors: A Critical Appraisal of Current SystemsJanne T BackmanAdvances in Pharmacology (San Diego, Calif.)|May 27, 2018
Cytochrome P450 in Pharmacogenetics: An UpdateAleksi Tornio, Janne T BackmanSteroids|December 8, 2000
The levonorgestrel intrauterine system in contraceptionP Lähteenmäki, I Rauramo, T BackmanVirchows Archiv : an International Journal of Pathology|September 16, 1998
Immunohistochemical localization of metallothionein in synovial tissue of patients with chronic inflammatory and degenerative joint diseaseJ T Backman, I Siegle, P FritzClinica Chimica Acta; International Journal of Clinical Chemistry|May 11, 2020
Comparison of LC-MS/MS and chemiluminescent immunoassays for immunosuppressive drugs reveals organ dependent variation in blood cyclosporine a concentrationsAnna Becker, Janne T Backman, Outi ItkonenClinical Pharmacokinetics|June 20, 2008
Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatinPertti J Neuvonen, Janne T Backman, Mikko NiemiBritish Journal of Clinical Pharmacology|November 19, 2025
Clinical pharmacology consultations and their implementation in clinical decision makingMirjam Kauppila, Janne T Backman, Outi Lapatto-ReiniluotoBritish Journal of Clinical Pharmacology|August 16, 2011
CYP2C8 but not CYP3A4 is important in the pharmacokinetics of montelukastTiina Karonen, Pertti J Neuvonen, Janne T BackmanEuropean Journal of Clinical Pharmacology|July 13, 2006
The CYP2C8 inhibitor gemfibrozil does not increase the plasma concentrations of zopicloneAleksi Tornio, Pertti J Neuvonen, Janne T BackmanEuropean Journal of Clinical Pharmacology|October 9, 2010
The CYP2C8 inhibitor gemfibrozil does not affect the pharmacokinetics of zafirlukastTiina Karonen, Pertti J Neuvonen, Janne T BackmanPageof 23